TRINCE
Desconocido
Penphomet: PEN photoporation for the genetic engineering of therapeutic mesenchymal stromal cells and T cells
TRINCE
tramitó un
HORIZON EUROPE:
HORIZON-EIC-2023-TRANSITION-01
Adoptive cell therapy has emerged as a promising strategy to treat cancer. It relies on patient-derived cells, such as T cells and mesenchym...
2024-02-26 - 2027-02-28 | Financiado
2024-02-26 - 2027-02-28 | Financiado
* No se disponen de datos de la empresa actual.